The Nuclear Medicine & Life Sciences Strategic Consultancy
Predict Ltd provides strategic and transactional consultancy to clients seeking to create value in the Nuclear Medicine / Imaging / Radiotherapeutics space.
Value Based Pricing
Customer & Patient Focused
Dependability & Security of Supply
Innovation & Disruption
Building Teams & Growth
360 Degree Understanding
Current Assignments & Ongoing Partnerships
• Advising the Australian Government, through ANSTO – appointed to develop an independent business case that expertly considers the options available to provide a secure medium to long term sustainable future of nuclear medicine supply to patients in Australia.
• Advising a leading Private Equity Company regarding the possible sale of a global Nuclear Medicine Company.
• Strategic Advisor to Urenco Limited regarding Medical Isotopes
• Strategic Advisor to SHINE Medical
Said of Martyn Coombs:
“Martyn is a recognized leader in the nuclear medicine industry, with an impressive track record building forward-looking teams and industry-leading companies.”
Mr. Coombs holds a degree in Mathematics, together with an MBA with distinction from Warwick Business School.
Martyn Coombs
Martyn Coombs is a recognised Industry Leader in Nuclear Medicine and Imaging.
As President, he led Jubilant DraxImage through a period of rapid organic growth – tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill, a key PET Cardiology product.
Mr. Coombs has also held senior leadership roles at GE Healthcare and Nihon Medi-Physics, where he was the number two Executive. He has served as CEO of Asterand plc, a public Life Sciences company, where in 2008 he received an award from the Financial Times for the top performing stock on the London Stock Exchange, out of over 2,000 companies. Most recently Mr. Coombs served as CEO of ImaginAb.
He has lived and worked in the US, Japan, Canada and Europe.
Tamara Mills is Managing Director of ImpactxHealth, a high calibre innovation commercialization organization, supporting the growth and development of the Australasian health innovation ecosystem and facilitating strategic investments in the equity and equity-linked securities of early stage to mid-tier ASX listed companies involved in the development of breakthrough medical and healthcare technologies.
Tamara has extensive experience in the commercialization of innovative medical technologies across the United States, Japan, Brazil, Europe and Australia, having held executive level positions within Australia and internationally at both publicly listed and private companies.
Tamara has a strong track record in portfolio asset management in commercial radiopharmaceutical space having previously managed the pipeline product portfolio for Jubilant life sciences.
Ms. Mills has held several board positions in the health technology sector, and she is active in the field of diagnostic and therapeutic technology development, and most recently held the position of Chair of the Health Policy, Regulatory and Reimbursement committee for the North American Radiopharmaceutical Industry organization CORAR in addition to holding a key leadership role for the Medical Imaging Technology Alliance.
Ms. Mills currently holds the position of Co-Chair at Ausbiotech and is on the investment advisory board of the largest university venture capital fund in Australia.
Tamara Mills
Tamara Mills says:
“There is always something new to learn, which is what makes the start up environment so exciting.”
Ms. Mills has an MBA, Masters in Health Economics, a Degree in Applied Nuclear Physics and a qualification in New Ventures Leadership from the Massachusetts Institute of Technology.
Contact Predict Ltd.
Please send us your contact details in the form below:
Predict Ltd provides strategic and transactional consultancy to clients seeking to create value in the Nuclear Medicine / Imaging / Radiotherapeutics space.